BiotechTube

Naloxegol

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid-induced Constipation

Conditions

Opioid-induced Constipation

Trial Timeline

Sep 21, 2017 → Oct 31, 2019

NCT ID
NCT04173858

About Naloxegol

Naloxegol is a pre-clinical stage product being developed by Kyowa Kirin for Opioid-induced Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT04173858. Target conditions include Opioid-induced Constipation.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (4)

NCT IDPhaseStatus
NCT03638440Pre-clinicalCompleted
NCT04173858Pre-clinicalCompleted
NCT02813148Pre-clinicalCompleted
NCT02099591Phase 1Completed

Competing Products

20 competing products in Opioid-induced Constipation

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
NKTR-118 + Usual careAstraZenecaPhase 3
77
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
Naloxegol + Placebo Oral CapsuleAstraZenecaPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
CB-5945 + PlaceboMerckPhase 3
77
CB-5945 + PlaceboMerckPhase 3
77
CB-5945 + PlaceboMerckPhase 3
77
CB-5945 + PlaceboMerckPhase 3
77
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Methylnaltrexone bromide + PlaceboPfizerPhase 2
51
ALKS 37 + PlaceboAlkermesPhase 2
49

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85